Free tool
FAERS Monitor: Invega
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 022043 or its brand name (Invega, Paliperidone). Reports on generic versions are filed under their own applications.
Reports
23,466
Serious
11,599
49% of reports
Hospitalization
4,806
Death reported
845
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- injury4,330
- gynaecomastia3,666
- drug ineffective1,795
- abnormal weight gain1,662
- off label use1,565
- weight increased1,390
- hyperprolactinaemia1,272
- galactorrhoea1,060
- sedation762
- dyskinesia717
- dystonia715
- treatment noncompliance684
- suicide attempt672
- schizophrenia670
- product use in unapproved indication632
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2007 | 696 |
| 2008 | 743 |
| 2009 | 650 |
| 2010 | 524 |
| 2011 | 687 |
| 2012 | 783 |
| 2013 | 652 |
| 2014 | 966 |
| 2015 | 2,359 |
| 2016 | 4,208 |
| 2017 | 3,453 |
| 2018 | 910 |
| 2019 | 847 |
| 2020 | 814 |
| 2021 | 812 |
| 2022 | 932 |
| 2023 | 924 |
| 2024 | 801 |
| 2025 | 1,024 |
| 2026 | 681 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,030,693 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| hyperprolactinaemiaSignal | 1,272 | 218.5 | 205.8 | 221,318 |
| galactorrhoeaSignal | 1,060 | 176.9 | 165.8 | 154,743 |
| abnormal weight gainSignal | 1,662 | 139.2 | 132.4 | 197,338 |
| gynaecomastiaSignal | 3,666 | 120.3 | 116.5 | 382,964 |
| injurySignal | 4,330 | 58.8 | 57.1 | 231,430 |
| schizophreniaSignal | 670 | 52.2 | 48.4 | 31,793 |
| dystoniaSignal | 715 | 34.3 | 31.8 | 22,230 |
| sedationSignal | 762 | 26.8 | 25.0 | 18,396 |
| dyskinesiaSignal | 717 | 16.1 | 15.0 | 9,965 |
| treatment noncomplianceSignal | 684 | 11.3 | 10.5 | 6,372 |
| suicide attemptSignal | 672 | 10.0 | 9.3 | 5,412 |
| weight increasedSignal | 1,390 | 5.6 | 5.3 | 5,260 |
| product use in unapproved indicationSignal | 632 | 2.3 | 2.1 | 462 |
| off label use | 1,565 | 1.6 | 1.5 | 369 |
| drug ineffective | 1,795 | 1.2 | 1.2 | 76 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.